Disease-modifying antirheumatic drug (DMARD)/steroid treatment received over 10 years of follow-up
| DMARD/steroid treatment between previous and current follow-up, n (%) | ||||||
|---|---|---|---|---|---|---|
| Year of follow-up | Cohort (n) | Treated between previous and current follow-up, n (%) | Sulfasalazine (SSZ) | Methotrexate (MTX) | Steroid (Ss) | Other |
| 0* | 1084 | 226 (21) | 135 (60) | 15 (7) | 72 (32) | 17 (8) |
| 1 | 1025 | 450 (44) | 283 (63) | 69 (15) | 139 (31) | 36 (8) |
| 2 | 961 | 418 (43) | 225 (54) | 91 (22) | 128 (31) | 40 (10) |
| 3 | 924 | 396 (43) | 194 (49) | 114 (29) | 124 (31) | 38 (10) |
| 5 | 855 | 374 (44) | 164 (44) | 144 (39) | 127 (34) | 32 (9) |
| 7 | 732 | 305 (42) | 113 (37) | 150 (49) | 98 (32) | 25 (8) |
| 10 | 664 | 293 (44) | 108 (37) | 159 (54) | 95 (32) | 22 (8) |
| Ever DMARD/steroid treatment by follow-up, n (%) | ||||||
|---|---|---|---|---|---|---|
| Year of follow-up | Cohort (n) | Ever treated by follow-up, n (%) | Sulfasalazine (SSZ) | Methotrexate (MTX) | Steroid (Ss) | Other |
| 0 | 1084 | 226 (21) | 135 (60) | 15 (7) | 72 (32) | 17 (8) |
| 1 | 1025 | 453 (44) | 285 (63) | 70 (15) | 139 (31) | 41 (9) |
| 2 | 961 | 464 (48) | 298 (64) | 101 (22) | 151 (33) | 56 (12) |
| 3 | 924 | 466 (50) | 308 (66) | 134 (29) | 156 (33) | 60 (13) |
| 5 | 855 | 444 (52) | 294 (66) | 170 (38) | 161 (36) | 64 (14) |
| 7 | 732 | 374 (51) | 255 (68) | 182 (49) | 142 (38) | 58 (16) |
| 10 | 664 | 361 (54) | 255 (71) | 192 (53) | 142 (39) | 62 (17) |
↵* Treated since symptom onset to baseline.